Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA48981
Max Phase: Preclinical
Molecular Formula: C32H52N8O7
Molecular Weight: 660.82
Molecule Type: Protein
Associated Items:
ID: ALA48981
Max Phase: Preclinical
Molecular Formula: C32H52N8O7
Molecular Weight: 660.82
Molecule Type: Protein
Associated Items:
Canonical SMILES: CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCN=C(N)N)C(=O)N[C@@H](CC(C)C)C(=O)O
Standard InChI: InChI=1S/C32H52N8O7/c1-5-19(4)26(29(44)38-24(31(46)47)16-18(2)3)39-27(42)23(17-20-10-12-21(41)13-11-20)37-28(43)25-9-7-15-40(25)30(45)22(33)8-6-14-36-32(34)35/h10-13,18-19,22-26,41H,5-9,14-17,33H2,1-4H3,(H,37,43)(H,38,44)(H,39,42)(H,46,47)(H4,34,35,36)/t19-,22-,23-,24-,25-,26-/m0/s1
Standard InChI Key: ORFISQWLBSTJAE-KTHKBMNISA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Protein | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 660.82 | Molecular Weight (Monoisotopic): 660.3959 | AlogP: -0.06 | #Rotatable Bonds: 18 |
Polar Surface Area: 255.56 | Molecular Species: ZWITTERION | HBA: 8 | HBD: 8 |
#RO5 Violations: 2 | HBA (Lipinski): 15 | HBD (Lipinski): 11 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 4.11 | CX Basic pKa: 11.21 | CX LogP: -1.27 | CX LogD: -1.64 |
Aromatic Rings: 1 | Heavy Atoms: 47 | QED Weighted: 0.06 | Np Likeness Score: 0.32 |
1. Cain GA, Christos TE, Johnson AL, Pottorf RS, Tam S, Schmidt WK. (1993) Identification of simpler analogs of neurotensin(913) which retain antinociceptive activity, 3 (8): [10.1016/S0960-894X(00)80059-1] |
2. Lundquist JT, Dix TA.. (1999) Preparation and receptor binding affinities of cyclic C-terminal neurotensin (8-13) and (9-13) analogues., 9 (17): [PMID:10498212] [10.1016/s0960-894x(99)00420-5] |
3. St-Pierre S, Lalonde JM, Gendreau M, Quirion R, Regoli D, Rioux F.. (1981) Synthesis of peptides by the solid-phase method. 6. Neurotensin, fragments, and analogues., 24 (4): [PMID:7265123] [10.1021/jm00136a004] |
4. Lundquist JT, Büllesbach EE, Dix TA.. (2000) Synthesis of neurotensin(9-13) analogues exhibiting enhanced human neurotensin receptor binding affinities., 10 (5): [PMID:10743946] [10.1016/s0960-894x(00)00018-4] |
5. Lundquist JT, Dix TA.. (1999) Synthesis and human neurotensin receptor binding activities of neurotensin(8-13) analogues containing position 8 alpha-azido-N-alkylated derivatives of ornithine, lysine, and homolysine., 42 (23): [PMID:10579853] [10.1021/jm9903444] |
6. Rivier JE, Lazarus LH, Perrin MH, Brown MR.. (1977) Neurotensin analogues. Structure--activity relationships., 20 (11): [PMID:915901] [10.1021/jm00221a011] |
Source(1):